Whole-exome and transcriptome profiling of 150 metastatic castration-resistant prostate cancer found that more than 19% of them have at least one mutation in BRCA1, BRCA2, ATM and CDK12 [37]. This evidence concerns the gene CDK12 and Familial prostate cancer.